Research programme: hypersulfated disaccharides - IVAX Corporation
Latest Information Update: 15 Jan 2008
At a glance
- Originator IVAX Corporation
- Class Disaccharides
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Hypersensitivity
Most Recent Events
- 15 Jan 2008 No development reported - Preclinical for Allergy in USA (Inhalation)
- 19 Jun 2006 Preclinical trials in Allergy in USA (Inhalation)